BCAX Stock Analysis: Buy, Sell, or Hold?
BCAX - Bicara Therapeutics Inc. Common Stock
$20.11
-0.12 (-0.59%)
▼
5d:
-12.26%
30d:
-16.24%
90d:
+42.83%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 19, 2026
TODAY
Smart Money Accumulation
BCAX is down 10.4% this week, but smart money is accumulating calls. Top strike: $22.5 2026-06-18 with 93 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When BCAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BCAX is down 12.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BCAX is down 12.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCAX is currently trading at $20.11, which is considered oversold relative to its 30-day fair value range of $21.31 to $23.49.
Technical Outlook: Technically, BCAX is showing support break momentum. The price is currently testing key support at $19.87. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.46 (+55.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCAX is showing support break momentum. The price is currently testing key support at $19.87. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $31.46 (+55.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$21.31 -
$23.49
Company Quality Score
52/100
(HOLD)
Options IV Signal
8th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 8th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 55.5% below Wall St target ($31.46)
- WARNING: Recommendation downgraded due to -12.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$21.31 -
$23.49
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.76
(13.7%)
Support & Resistance Levels
Support Level
$19.87
Resistance Level
$23.80
Current Trend
Support Break
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.66
Wall Street Target
$31.46
(+55.5%)
Share & Embed Analysis
Last updated: May 18, 2026 9:48 AM ET
Data refreshes hourly during market hours. Next update: 10:48 AM
Data refreshes hourly during market hours. Next update: 10:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Ivan Hyep
SELL
9200 shares
2026-04-21
Claire Mazumdar
SELL
15000 shares
2026-04-20
Ryan Cohlhepp
SELL
12500 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 55 HOLD |
